Objectives: To compare the clinical and bacteriological outcomes of pivmecillinam treatment for community-acquired urinary tract infections (UTIs) caused by ESBL-producing Escherichia coli versus non-ESBL-producing E. coli in an outpatient setting.
Methods: A prospective, multicentre, observational cohort study of women aged ≥16 years, with pivmecillinam-treated community-acquired UTIs caused by E. coli with or without ESBL production, recruited from primary care, was conducted in the period from April 2013 to August 2016. Eighty-eight women (mean age 49.4 years) with community-acquired UTIs caused by ESBL-producing E. coli were compared with a control group of 74 women (mean age 50.1 years).
Trial Registration: Regional Committees for Medical and Health Research Ethics (REC) in Norway, ID 2011/2214, and ClinicalTrials.gov, ID NCT01531023.
Results: The median time until symptom resolution after treatment initiation was 5 days for the ESBL cases and 3 days for the non-ESBL controls (P < 0.01). The proportion of women warranting a second antibiotic prescription in the follow-up period was higher for the ESBL cases [30/88 (34.1%) versus 10/72 (13.9%), P < 0.01]. Persistent bacteriuria was non-significantly more common among ESBL cases than in the control group [15/81 (18.5%) versus 6/67 (9.0%), P = 0.10]. A pivmecillinam dosage of 200 mg given three times daily for ≤5 days was associated with treatment failure (OR 4.77, 95% CI 1.40-19.44, P = 0.03) for the ESBL E. coli group. For the subgroup treated with 400 mg of pivmecillinam given three times daily there was no significantly increased OR for treatment failure between ESBL cases and the control group irrespective of treatment duration.
Conclusions: Pivmecillinam given at 400 mg three times daily gave comparable clinical and bacteriological cure rates in women with community-acquired E. coli UTIs irrespective of ESBL production.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dky230 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of Antibiotic Resistance Among Isolates of spp. and spp. in Wildlife and Their Environment from Portugal: A Positive Epidemiologic Outcome.
Pathogens
January 2025
MicroART-Antibiotic Resistance Team, Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.
One of the significant challenges facing modern medicine is the rising rate of antibiotic resistance, which impacts public health, animal health, and environmental preservation. Evaluating antibiotic resistance in wildlife and their environments is crucial, as it offers essential insights into the dynamics of resistance patterns and promotes strategies for monitoring, prevention, and intervention. and genera isolates were recovered from fecal samples of wild animals and environmental samples using media without antibiotic supplementation.
View Article and Find Full Text PDFAntimicrobial Resistance and Biofilm-Forming Ability in ESBL-Producing and Non-ESBL-Producing and Isolated from Canine Urinary Samples from Italy.
Antibiotics (Basel)
January 2025
Department of Veterinary Medicine and Animal Sciences, University of Milan, Via dell'Università 6, 26900 Lodi, Italy.
In dogs, bacterial urinary tract infections are a frequent cause of antimicrobial prescription, increasing the risk of selecting antibiotic-resistant bacteria. This study analyzed resistance patterns, the presence of extended-spectrum β-lactamases (ESBLs) and biofilm-forming capacity in and previously isolated from urine samples collected from 133 selected dogs admitted to the Veterinary Teaching Hospital of Milan, Italy, in 2021 and 2023. : The and isolates were bacteriologically and genetically analyzed.
View Article and Find Full Text PDFFecal carriage of carbapenemase and AmpC-β-lactamase producers among extended spectrum β-Lactamase-producing E. coli and Klebsiella spp. isolates in patients attending hospitals.
BMC Infect Dis
January 2025
Clinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Ouagdougou, 11 BP218, Burkina Faso.
Background: Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-PE), particularly Escherichia coli and Klebsiella pneumoniae, have been consistently associated with treatment failure, high mortality and morbidity. The emergence of carbapenem resistance among ESBL-PE strains exacerbates the antimicrobial resistance. However, data are very limited in developing countries as Burkina Faso.
View Article and Find Full Text PDFFecal carriage of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in South American camelids and biosecurity practices among farms in northern Italy.
Vet Res Commun
January 2025
Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, 26900, Italy.
South American camelids (SACs), particularly llamas (Lama glama) and alpacas (Vicugna pacos) are gaining popularity in Europe. Initially valued for their fiber and land management capabilities, these animals are now also kept for animal therapy, outdoor activities, and as companion animals. Despite their close interactions with humans and other animals, there is limited research on the transmission of microbes or antimicrobial resistance genes from SACs.
View Article and Find Full Text PDFPrevalence and genomic insights of carbapenem resistant and ESBL producing Multidrug resistant Escherichia coli in urinary tract infections.
Sci Rep
January 2025
Department of Biotechnology, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai, India.
Urinary tract infections are a common condition affecting people globally, with multidrug-resistant (MDR) Escherichia coli (E. coli) being a major causative agent. Antimicrobial susceptibility profiling was performed using the VITEK 2 automated system for 1254 E.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!